Want to see HK:0399 full AI Analyst Report?
Innovative Pharmaceutical Biotech (0399) Stock Statistics & Valuation Metrics
Total Valuation
Innovative Pharmaceutical Biotech has a market cap or net worth of HKD 231.21M. The enterprise value is HKD 2.52B.
- Market Cap
- HKD 231.21M
- Enterprise Value
- HKD 2.52B
Share Statistics
Innovative Pharmaceutical Biotech has 3,167,207,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 3,167,207,000
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Innovative Pharmaceutical Biotech’s return on equity (ROE) is 0.51 and return on invested capital (ROIC) is -1.29%.
- Return on Equity (ROE)
- 0.51
- Return on Assets (ROA)
- -0.32
- Return on Invested Capital (ROIC)
- -1.29%
- Return on Capital Employed (ROCE)
- -0.12
- Revenue Per Employee
- 104.55K
- Profits Per Employee
- -17.30M
- Employee Count
- 20
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Innovative Pharmaceutical Biotech is -0.36. Innovative Pharmaceutical Biotech’s PEG ratio is 0.00.
- PE Ratio
- -0.36
- PS Ratio
- 78.86
- PB Ratio
- -0.19
- Price to FCF
- -15.62
- Price to Operating Cash Flow
- -11.96
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Innovative Pharmaceutical Biotech had revenue of 2.09M and earned -345.94M in profits. Earnings per share was -0.20.
- Revenue
- 2.09M
- Gross Profit
- 188.00K
- Operating Income
- -13.26M
- Pretax Income
- -570.35M
- Net Income
- -345.94M
- EBITDA
- -296.99M
- Earnings Per Share (EPS)
- -0.20
Cash Flow
In the last 12 months, operating cash flow was 2.52M and capital expenditures 0, giving a free cash flow of 2.52M billion.
- Operating Cash Flow
- 2.52M
- Free Cash Flow
- 2.52M
- Free Cash Flow per Share
- -0.01
Dividends & Yields
Innovative Pharmaceutical Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -6.40%
- Earnings Yield
- -274.13%
Stock Price Statistics
- Beta
- 1.14
- 52-Week Price Change
- -70.33%
- 50-Day Moving Average
- 0.07
- 200-Day Moving Average
- 0.09
- Relative Strength Index (RSI)
- 32.25
- Average Volume (3m)
- ―
Important Dates
Innovative Pharmaceutical Biotech upcoming earnings date is Nov 27, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Jun 30, 2026
- Next Earnings Date
- Nov 27, 2026
- Ex-Dividend Date
- ―
Financial Position
Innovative Pharmaceutical Biotech as a current ratio of 0.01, with Debt / Equity ratio of -147.31%
- Current Ratio
- 0.01
- Quick Ratio
- 0.01
- Debt to Market Cap
- 3.34
- Net Debt to EBITDA
- -3.22
- Interest Coverage Ratio
- -0.05
Taxes
In the past 12 months, Innovative Pharmaceutical Biotech has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Innovative Pharmaceutical Biotech EV to EBITDA ratio is -3.92, with an EV/FCF ratio of -110.34.
- EV to Sales
- 556.99
- EV to EBITDA
- -3.92
- EV to Free Cash Flow
- -110.34
- EV to Operating Cash Flow
- -110.34
Balance Sheet
Innovative Pharmaceutical Biotech has HKD 18.07M in cash and marketable securities with HKD 1.09B in debt, giving a net cash position of -HKD 1.07B billion.
- Cash & Marketable Securities
- HKD 18.07M
- Total Debt
- HKD 1.09B
- Net Cash
- -HKD 1.07B
- Net Cash Per Share
- -HKD 0.34
- Tangible Book Value Per Share
- -HKD 0.59
Margins
Gross margin is 8.99%, with operating margin of -634.29%, and net profit margin of -16544.09%.
- Gross Margin
- 8.99%
- Operating Margin
- -634.29%
- Pretax Margin
- -27276.23%
- Net Profit Margin
- -16544.09%
- EBITDA Margin
- -14203.35%
- EBIT Margin
- -14837.25%
Scores
- Smart Score
- ―
- AI Score
- 42